GlucoLight Corp, Bethlehem, Pa, a development-stage company focused on blood glucose monitoring in the acute care environment, has announced that it has been awarded a US Patent for the technology that is the core of the company’s first product, the Sentris-100 glucose monitor.
The device relies on optical coherence tomography based technology to noninvasively monitor the concentration of glucose on the blood. It reads and monitors blood glucose by shining a light on a human or animal dermis and continuously monitoring the surface, while collecting the reflected light from within the tissue. The reflection spectrum is sensitive to glucose concentration, which allows for a noninvasive measure of glucose levels in the blood.
The monitor, which is in clinical testing, needs regulatory clearance and is not yet for sale. The company recently completed its first hypoglycemic clamping study, which measured blood glucose fluctuations in volunteer subjects with Type 1 diabetes. An ICU clinical study was conducted in May at the Penn State Hershey Medical Center in Hershey, Pa and the Providence Heart & Vascular Institute at Providence St. Vincent Medical Center in Portland, Ore.
